NSE filing, NSE: INDUSTOWER. Summary written from the filing by ALFA Finder's alert engine.
Indus Towers Ltd: key numbers
- Share price
- ₹387.00
- Market cap
- ₹1,02,097 Cr
- Revenue (annual)
- ₹32,493 Cr
- Net profit (annual)
- ₹7,145 Cr
- P/E (TTM)
- 14.4×Sector 38.5×
- Promoter holding
- 51.26%+0.00% QoQ
- FII holding
- 21.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indus Towers Ltd
All →Indus Towers Earnings Call Transcript: Key Takeaways
Indus Towers delivered steady operational growth driven by strong co-location additions and network expansion from a major customer.
Indus Towers Results Update
Indus Towers released its Q2 and half-year quarterly report with audited results. Headline revenue and profit figures are not visible in these pages.
Indus Towers Q2 FY27 Results: Net Profit ₹1,793 Cr, Down 2.5% YoY
Indus Towers Ltd reported revenue from operations of ₹8,516 Cr (+4.0% YoY) and net profit of ₹1,793 Cr (-2.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,793 Cr · -2.5% YoY
Indus Towers Other Announcement
The company submitted its quarterly shareholding pattern for the period ending September 30, 2026, as required by SEBI regulations.
Indus Towers Board Meeting Date
Indus Towers announced a board meeting on October 27, 2026, to consider and approve its audited financial results for the second quarter ended September 30, 2026.
Indus Towers Other Announcement
Indus Towers Limited has been assigned an ESG Rating of 69.86 (Leader) by Niche Ninety Nine Capability and Certifications (OPC) Private Limited.
Other other announcement announcements
All →Kansai Nerolac Paints Other Announcement
Kansai Nerolac authorised Pravin Chaudhari, Yash Ahuja and Rukmini Subramanian to determine material events from 1 December 2026. It only lists KMP and contact details.
Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Vineet Laboratories Other Announcement
Vineet Laboratories' board appointed SVRL & Co. as statutory auditors, subject to shareholder approval. The five-year term runs from the 10th AGM to the 16th AGM.
Physicswallah Other Announcement
Physicswallah's IPO monitoring report flags a deviation from offer objects for the quarter ended September 30, 2026. The diverted funds were restored on October 30, 2026.
Gujarat Kidney and Super Speciality Other Announcement
Gujarat Kidney filed Brickwork's monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation from the IPO fund-utilisation objects.
PDS Other Announcement
PDS Limited submitted the CRISIL Ratings monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation in the utilisation of its QIP proceeds.